Independent Advisor Alliance Reduces Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Independent Advisor Alliance lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,155 shares of the medical research company’s stock after selling 104 shares during the quarter. Independent Advisor Alliance’s holdings in IQVIA were worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in IQV. Versant Capital Management Inc raised its position in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA in the 2nd quarter worth $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new position in IQVIA during the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA during the second quarter valued at about $29,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 0.1 %

Shares of IQV opened at $201.43 on Friday. The business’s 50 day simple moving average is $219.50 and its 200-day simple moving average is $226.40. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.43, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IQV. Robert W. Baird lowered their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Truist Financial lowered their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Finally, Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.